Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
semaglutide | increase | glycemic control | adult with CFRD, obesity, and clinical insulin resistance | - | improved | #1 |
semaglutide | decrease | insulin requirements | adult with CFRD, obesity, and clinical insulin resistance | - | reduced | #2 |
semaglutide | decrease | weight loss | adult with CFRD, obesity, and clinical insulin resistance | 10.5 kg | resulted in | #3 |
semaglutide | decrease | body mass index | adult with CFRD, obesity, and clinical insulin resistance | from 38.5 kg/m² to 33.5 kg/m² | reduced | #4 |
semaglutide | decrease | hemoglobin A1c | adult with CFRD, obesity, and clinical insulin resistance | from 8.5% to 6.8% | reduced | #5 |
semaglutide | decrease | total daily insulin dose | adult with CFRD, obesity, and clinical insulin resistance | from 120 units to 40 units | reduced | #6 |
glucagon-like peptide 1 receptor agonists | neutral | - | carefully selected patients | - | may provide additional benefits | #7 |
BACKGROUND/OBJECTIVE: Cystic fibrosis (CF)-related diabetes (CFRD) is a common extrapulmonary complication of CF, with increasing prevalence. As individuals with CF live longer, obesity rates are increasing, leading to an emerging phenotype called CFRD with metabolic syndrome. The objective of this report is to describe the use of semaglutide in an adult with CFRD, obesity, and clinical insulin resistance. CASE REPORT: A 32-year-old man with CF, pancreatic insufficiency, obesity, and poorly controlled CFRD presented with worsening blood sugar control, increasing insulin requirements, and a strong family history of metabolic syndrome. His body mass index was 38.5 kg/m DISCUSSION: Although insulin is the primary treatment for CFRD, glucagon-like peptide 1 receptor agonists may provide additional benefits in carefully selected patients. CONCLUSION: This case highlights the potential benefits of glucagon-like peptide 1 receptor agonists in CFRD with metabolic syndrome and emphasizes the need for further investigation.